Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cytokinetics plunges as tirasemtiv fails to BENEFIT-ALS

This article was originally published in Scrip

Executive Summary

Cytokinetics lost $303m worth of market value on 25 April after the company reported that its drug tirasemtiv caused a greater numerical loss of function for individuals with amyotrophic lateral sclerosis (ALS) than placebo in the 711-patient Phase IIb BENEFIT-ALS clinical trial.


Related Content

Seven Clinical Trial Read-Outs Due In Q4
Cytokinetics Seeks ALS Success By Focusing On Lung Function
Astellas Targets ALS In Expansion Of Cytokinetics Alliance


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts